Vitamin D levels do not cause vitamin-drug interactions with dexamethasone or dasatinib in mice.
Vitamin D3 (VD3) induces intestinal CYP3A that metabolizes orally administered anti-leukemic chemotherapeutic substrates dexamethasone (DEX) and dasatinib potentially causing a vitamin-drug interaction. To determine the impact of VD3 status on systemic exposure and efficacy of these chemotherapeutic...
Guardado en:
Autores principales: | Kavya Annu, Kazuto Yasuda, William V Caufield, Burgess B Freeman, Erin G Schuetz |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2b256692a0f8435c85bc1753e5748a00 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Warfarin drug interaction with vitamin K and other foodstuffs
por: Minighin,Elaine C., et al.
Publicado: (2020) -
Vitamin D deficiency in elderly: Risk factors and drugs impact on vitamin D status
por: Hasan Kweder, et al.
Publicado: (2018) -
Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice
por: Emanuel J. Novais, et al.
Publicado: (2021) -
Development of In Vitro and In Vivo Evaluation Systems for Vitamin D Derivatives and Their Application to Drug Discovery
por: Kaori Yasuda, et al.
Publicado: (2021) -
Vitamin D, Magnesium and Their Interactions: A Review
por: Zeinab Shahsavani, et al.
Publicado: (2021)